Table 2 Vaccine groups used in Trial I and Trial II.
From: A single dose polyanhydride-based nanovaccine against paratuberculosis infection
Group | Dosage of protein | |
|---|---|---|
Trial Ia | PAN-Lysate | 75 µg soluble + 25 µg encapsulated |
Lysate (no PAN) | 100 µg soluble | |
Mycopar® | 100 µL | |
PBS | 100 µL | |
Trial IIb | PAN-Lysate | 75 µg soluble + 25 µg encapsulated |
PAN-Cf | 75 µg soluble + 25 µg encapsulated | |
PAN-Cf + Lysate | 75 µg soluble + 25 µg encapsulated | |
LipN | 108 C.F.U. | |
Mycopar® | 100 μL | |
PBS | 100 μL |
